Colorectal Cancer | Specialty

Dr. Eckhardt on Angiogenesis Inhibition in Metastatic CRC

August 20th 2013

Gail Eckhardt, MD, from the University of Colorado Denver and Health Sciences Center, discusses the future role of aflibercept for patients with metastatic colorectal cancer.

New Phase III Trial

August 19th 2013

PACES trial will evaluate 2 drugs to prevent colon adenomas.

Dr. Lenz Describes Excitement Over Advances in GI Cancer

August 16th 2013

Heinz-Josef Lenz, MD, from the USC Norris Comprehensive Cancer Center, believes this is an exciting time in the field of gastrointestinal cancers, as more tools become available to select the most effective treatment for each patient.

RAS Mutation Status Key to Panitumumab Use in mCRC

July 30th 2013

The presence or absence of RAS mutations should dictate use of panitumumab in combination with FOLFOX chemotherapy for patients with metastatic colorectal cancer.

Dr. Kaufman on the Importance of the Immunoscore

July 16th 2013

Howard L. Kaufman, MD, Rush University Medical Center, discusses the implications of the Immunoscore for the treatment of patients with cancer.

Dr. Marc Peeters on the Aflibercept Toxicity Profile

July 9th 2013

Marc Peeters, MD, PhD, from the Antwerp University Hospital, discusses the importance of properly managing the toxicities associated with aflibercept when treating patients with metastatic colorectal cancer.

IV Calcium/Magnesium Has No Effect on Oxaliplatin-Induced Neuropathy

July 6th 2013

Intravenous calcium plus magnesium given before or after adjuvant FOLFOX chemotherapy has absolutely no effect on the development of sensory neurotoxicity induced by oxaliplatin.

Dr. Lenz Explores KRAS/NRAS Mutations in Colorectal Cancer

July 6th 2013

Heinz-Josef Lenz, MD, from the USC Norris Comprehensive Cancer Center, discusses the potential predictive impact of KRAS and NRAS mutations in metastatic colorectal cancer.

Simple, Inexpensive Blood Test Poised to Be a Real "Game Changer" in CRC Screening

July 6th 2013

A simple and inexpensive blood test is being developed that can be used to screen patients for premalignant colorectal cancer lesions which, once perfected, will be a real game changer.

Better Responders in VELOUR Derive Enhanced Benefit From Aflibercept

July 6th 2013

Better responders within a cohort of patients from the VELOUR study derive enhanced benefit from aflibercept when combined with FOLFIRI, a post-hoc analysis of the study shows.

Dr. Ruff on Selecting Anti- Angiogenic Agents in mCRC

July 5th 2013

Paul Ruff, MD, from the University of Witwatersrand, Johannesburg, South Africa, elaborates on factors that can be utilized to select an appropriate antiangiogenic therapy as a second-line treatment in metastatic colorectal cancer.

Dr. Mitchell on a Subgroup Analysis of the VELOUR Trial

June 26th 2013

Edith Mitchell, MD, FACP, from Thomas Jefferson University, gives an overview of the North American subgroup analysis of the VELOUR trial.

Lack of Discontinuation of Statin Therapy After Diagnosis of End-Stage Cancer

June 14th 2013

The diagnosis of end-stage cancer rarely led to the clinically indicated discontinuation of statin therapy when prescribed for primary prevention.

Dr. Heinemann Reviews the FIRE-3 Trial Results

June 2nd 2013

Volker Heinemann, MD, PhD, from the University of Munich, discusses results from the phase III FIRE-3 trial that looked at FOLFIRI plus bevacizumab or cetuximab as a first-line treatment for patients with wild-type KRAS metastatic colorectal cancer.

Cetuximab OS Results Top Bevacizumab in mCRC

June 2nd 2013

Frontline cetuximab plus FOLFIRI chemotherapy improved overall survival by 3.7 months versus bevacizumab plus FOLFIRI in patients with KRAS wild-type metastatic colorectal cancer.

Adding Cetuximab to Chemotherapy Increases Resection Rates of Colorectal Liver Metastases and Extends Survival

May 23rd 2013

The addition of cetuximab to chemotherapy as first-line treatment of KRAS wild-type unresectable colorectal liver metastases resulted in a higher rate of resection and longer survival than chemotherapy alone

High Levels of Cardiovascular Fitness Reduces the Risk of Developing and Dying From Cancer

May 15th 2013

Men with a high level of cardiovascular fitness at middle age had a reduced risk of developing and dying from lung and colorectal cancer later in life.

What Is the Role of Maintenance Therapy in Cancer Care?

May 1st 2013

Experts provide an in-depth look at the treatment strategy in patients with solid tumors, specifically looking at the role of maintenance therapy.

Conclusion: Optimal Side Effect Management in CRC

April 2nd 2013

Case Study: Treating Metastatic Colorectal Cancer

April 2nd 2013